Results 201 to 210 of about 15,495 (255)

[ESBL – risk factors and treatment].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2016
openaire   +1 more source

ESBLs: A Clear and Present Danger? [PDF]

, 2012
Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme-producing organisms are associated with a higher morbidity and mortality and greater fiscal burden ...
John Clark, Rishi H.-P. Dhillon
openaire   +2 more sources

CTX-M: changing the face of ESBLs in the UK [PDF]

Journal of Antimicrobial Chemotherapy, 2005
The UK has experienced a sudden rise in extended-spectrum ß-lactamase (ESBL) rates, largely due to the appearance and spread of Escherichia coli producing CTX-M-15 type ß-lactamase.
P M Hawkey, Livermore D M
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Characterization of ESBL disseminating plasmids

Infectious Diseases, 2015
Bacteria producing extended-spectrum β-lactamases (ESBLs) constitute a globally increasing problem that contributes to treatment complications and elevated death rates. The extremely successful dissemination by ESBL-producing Enterobacteriaceae during the latest decades is a result of the combination of mobilization, evolution and horizontal spread of ...
Alma, Brolund, Linus, Sandegren
openaire   +2 more sources

Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen

Journal of Clinical Microbiology, 1996
Resistance to contemporary broad-spectrum beta-lactams, mediated by extended-spectrum beta-lactamase (ESBL) enzymes, is an increasing problem worldwide. The Etest (AB Biodisk, Solna, Sweden) ESBL screen uses stable gradient technology to evaluate the MIC of ceftazidime alone compared with the MIC of ceftazidime with clavulanic acid (2 micrograms/ml) to
M G, Cormican, S A, Marshall, R N, Jones
openaire   +2 more sources

Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections

Journal of Infection, 2007
This study was designed to compare cefepime exposures with microbiological outcomes in ESBL and non-ESBL infections and determine the pharmacodynamic profiles associated with successful outcome.Cefepime pharmacodynamic exposures of unbound drug [time above MIC (fT>MIC), minimal concentration over MIC (fC(min)/MIC), and area under the curve over MIC ...
Su Young, Lee, Joseph L, Kuti, David P, Nicolau   +2 more
openaire   +2 more sources